The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMPN 2026 | Interpreting symptom control in the SENTRY trial of selinexor plus ruxolitinib in myelofibrosis
John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses results from the Phase III SENTRY trial (NCT04562389) of selinexor plus ruxolitinib in patients with myelofibrosis, highlighting that although the combination did not meet the symptom response co-primary endpoint, symptoms still improved from baseline and a more nuanced view should be taken when interpreting these results. He highlights that, given the potential ceiling effect on symptom improvement seen with ruxolitinib alone, this endpoint may be inadequate in the era of JAK inhibitors. This interview took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
